Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Deraya University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07416409CT.gov Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer | — | Completed | — | — | — |
NCT03500380CT.gov A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | — | Unknown | — | — | — |
NCT01875666CT.gov Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | — | Completed | — | — | — |
NCT01557764CT.gov Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT01499160CT.gov Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer | — | Terminated | — | — | — |
NCT01273610CT.gov Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01272141CT.gov A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT01218529CT.gov Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors | — | Completed | — | — | — |
NCT00807859CT.gov Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00826267CT.gov 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT00073528CT.gov Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lapatinib (this asset) | Deraya University | P3 | B · 59 |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Eribulin Monomethanesulfonate | Fudan University | P4 | BB |
| Palbociclib | Eli Lilly and Company | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for Lapatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Male Breast Carcinoma | — | P3 | BB · 67 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lapatinib in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lapatinib-breast-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →